Section of Cardiology
Associate Professor of Medicine
Medical Director, Cardiac Care Unit
Referring Physician Access Line: 1-877-DOM-2730
|BA||1994||Stanford University||International Relations
|MD||1999||University of Illinois, Chicago, IL||
|Residency||2002||Northwestern University||Internal Medicine
|Fellowship||2005||UCLA Olive View/West LA VA||Cardiovascular Disease
|Fellowship||2006||UCLA Harbor/Good Samaritan Hospital||Interventional Cardiology
Working at the University of Chicago has allowed Dr. Shah to blend his clinical and translational research interests. Dr. Shah is currently studying the role of inflammatory cytokines and progenitor cells in a large animal model of ischemic arrest. Studying what influences survival in animals who have suffered cardiac arrest may directly translate into implementing therapies that save the lives of thousands of patients a year who suffer from cardiac arrest. This blends very well with his studies of implementing systems of care that deliver the best possible care to patients who suffer from acute myocardial infarctions. Additionally, he is researching the role of intravascular ultrasound during angioplasty procedures in patients who are suffering from acute myocardial infarction as well as different novel therapies that can help save heart muscle during a heart attack. He is also the primary investigator on a clinical study that is investigating the role of peripheral arterial disease in men who have erectile dysfunction and the primary investigator of a trial that is studying the clinical safety of a same-day discharge program for patients undergoing angioplasty as an outpatient.
Treatment of coronary artery disease using the latest techniques including angioplasty, stents, atherectomy, and thrombectomy; utilization of minimally invasive techniques to treat carotid and peripheral arterial disease; treatment of structural heart disease including the percutaneous repair of atrial and ventricular septal defects, coronary and peripheral fistulae, and valvular stenosis; and treatment of survivors of cardiac arrest with aggressive revascularization and hypothermia.
- Beohar N, Flaherty J, Davidson CD, Maynard RC, Robbins JC, Shah AP, Choi JW, MacDonald LA, Jorgensen JP, Pinto JV, Chandra S, Klaus HM, Wang NC, Harris KR, Decker R, Bonow RO, Antirestenotic Effects of a Locally Delivered Caspase Inhibitor in a Balloon Injury Model. Circulation 2004; 109(1): 108-113.
- Shah AP, Niemann JT, Youngquist SY, Josephson G, Rosborough JP. Endothelin-1 is Not Predictive of Ventricular Ectopy or Ventricular Fibrillation in Acute Myocardial Ischemia. J Interferon Cytokine Res. 2008 Nov;28(11):639-41.
- Shah AP, Youngquist SY, Heyming T, Rosborough JP, Niemann JT. Plasma Endothelin-1 Level at the Onset of Ischemic Ventricular Fibrillation Predicts Resuscitation Outcome. Resuscitation. 2009 May;80(5):580-3.
- Niemann JT, Rosborough JP, Youngquist ST, Shah AP. Infliximab Attenuates Early Postresuscitation Myocardial Dysfunction in a Swine Cardiac Arrest Model. Journal of Critical Care Medicine. 2010;38(4):1162-7.
- Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, Makkar RR. Drug Eluting Stenting is Superior to Bare Metal Stents in Saphenous Vein Grafts. Catheterization and Cardiovascular Interventions 2005 Dec; 66(4):507-11